Lanreotide improves survival with enteropancreatic tumors

July 21, 2014
Lanreotide improves survival with enteropancreatic tumors

(HealthDay)—Lanreotide significantly improves survival among patients with metastatic enteropancreatic neuroendocrine tumors (grade 1 or 2), according to a study published in the July 17 issue of the New England Journal of Medicine.

Martyn E. Caplin, D.M., from Royal Free Hospital in London, and colleagues conducted a multinational study of with advanced, well-differentiated or moderately-differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors (grade 1 or 2 that originated in the pancreas, midgut, or hindgut, or were of unknown origin) and documented disease-progression status. Participants were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks.

The researchers found that, compared to placebo, lanreotide was associated with significantly prolonged progression-free (P < 0.001; hazard ratio for progression or death, 0.47). At 24 months, the estimated rates of progression-free survival were 65.1 percent in the lanreotide group and 33.0 percent in the group. In predefined subgroups, the therapeutic effect was generally consistent with that found in the overall population. Groups were similar in quality of life and overall survival. Diarrhea was the most common treatment-related adverse event (26 percent of the lanreotide group versus 9 percent of the ).

"Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic of grade 1 or 2 (Ki67 < 10 percent)," the authors write.

The study was funded by Ipsen, the manufacturer of lanreotide.

Explore further: Survival up after progression in HPV-positive oropharynx CA

More information: Full Text (subscription or payment may be required)

Related Stories

Survival up after progression in HPV-positive oropharynx CA

June 26, 2014
(HealthDay)—For patients with oropharynx cancer (OPC), human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study published online June 23 in the Journal of ...

Drug everolimus does not improve overall survival in patients with advanced liver cancer

July 1, 2014
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA.

Sorafenib shows success in advanced differentiated thyroid cancer patients

April 25, 2014
(Medical Xpress)—The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to a new study from researchers in the Abramson Cancer Center at the University ...

Abiraterone benefits chemo-naive with advanced prostate CA

December 12, 2012
(HealthDay)—For chemotherapy-naive patients with metastatic castration-resistant prostate cancer, abiraterone acetate correlates with improved radiographic progression-free survival, according to a study published online ...

Everolimus prolongs progression-free survival for patients with neuroendocrine tumors

November 29, 2011
Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of ...

Study compares survival for treatments of uncommon eye cancer

June 17, 2014
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.